MailPoet Page

[mailpoet_page]

Search for:

Meta

Log in
Entries feed
Comments feed
WordPress.org

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

Navigation

Home
About Synox
Scientific Background
Clinical Data
News & Press Releases
Contact Us

Recent News

SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumours November 16, 2020

Copyright SynOx Therapeutics

Terms & Conditions
Privacy Policy

Home
About
Scientific Background
Clinical Data
News & Press
Contact